2022 News

INFEX Therapeutics awarded Biomedical Catalyst grant for COV-X project

Alderley Park, Cheshire, U.K – Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18 month, £1m COV-X project, titled: “Optimisation...

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme

Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive...

MicroBioSensor launches QUICKCHECK™ designed in partnership with Smallfry

A device that can help speed the diagnosis of peritonitis in vulnerable kidney and liver failure patients. With results 10,000x faster than current methods, this portable and rapid detection device now means that nurses can carry out an instant le...

From our portfolio

Maxwellia

Pharmaceuticals

viewview our portfolio

Our Team

Hamish Graham

view complete team

Contact us

Tel: 01625 344300

email